Rotavirus genotypes in malaysia and universal rotavirus vaccination

Way Seah Lee; Benjamin Tze Ying Lim; Pei Fan Chai; Carl D. Kirkwood; Jimmy Kok Foo Lee

doi:10.4161/hv.21577

Rotavirus genotypes in malaysia and universal rotavirus vaccination

Way Seah Lee, Benjamin Tze Ying Lim, Pei Fan Chai, Carl D. Kirkwood, Jimmy Kok Foo Lee

Research output: Contribution to journal › Article › Research › peer-review

8 Citations (Scopus)

Abstract

Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published data on RV-A hospitalizations and genotypes, mortality on childhood GE and published genotype-specific efficacy data on two RV-A vaccines. Assuming a 95% vaccine coverage, the overall projected effectiveness was 75.7 to 88.1% for Rotateq® and 78.7 to 90.6% for Rotarix® against RVGE-related hospitalizations. The projected annual reduction in RVGE-related deaths was 27 to 32 deaths (from 34 deaths) for Rotateq® and 28 to 32 deaths annually forRotarix®. A universal RV-A vaccine is efficacious in reducing RVGErelated hospitalizations and mortality in Malaysia.

Original language	English
Pages (from-to)	1401-1406
Number of pages	6
Journal	Human Vaccines
Volume	8
Issue number	10
DOIs	https://doi.org/10.4161/hv.21577
Publication status	Published - Oct 2012
Externally published	Yes

Keywords

Group A rotavirus genotypes
Malaysia
Universal vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4161/hv.21577

Cite this

@article{85a4e4995bff4e63a92f5bd7090745f5,

title = "Rotavirus genotypes in malaysia and universal rotavirus vaccination",

abstract = "Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published data on RV-A hospitalizations and genotypes, mortality on childhood GE and published genotype-specific efficacy data on two RV-A vaccines. Assuming a 95% vaccine coverage, the overall projected effectiveness was 75.7 to 88.1% for Rotateq{\textregistered} and 78.7 to 90.6% for Rotarix{\textregistered} against RVGE-related hospitalizations. The projected annual reduction in RVGE-related deaths was 27 to 32 deaths (from 34 deaths) for Rotateq{\textregistered} and 28 to 32 deaths annually forRotarix{\textregistered}. A universal RV-A vaccine is efficacious in reducing RVGErelated hospitalizations and mortality in Malaysia.",

keywords = "Group A rotavirus genotypes, Malaysia, Universal vaccination",

author = "Lee, {Way Seah} and Lim, {Benjamin Tze Ying} and Chai, {Pei Fan} and Kirkwood, {Carl D.} and {Foo Lee}, {Jimmy Kok}",

note = "Funding Information: The present study was conducted as part of Asian Rotavirus Research Network (ARSN) III research initiatives into the burden of rotavirus disease in the Asia Pacific Region. The present study was funded by an unrestricted research grant from Merck Sharp and Dohme (MSD) Co., Ltd., MSD played no part in the design of the study, data collection or medical writing of the present study. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "2012",

month = oct,

doi = "10.4161/hv.21577",

language = "English",

volume = "8",

pages = "1401--1406",

journal = "Human Vaccines",

issn = "1554-8600",

publisher = "Taylor & Francis",

number = "10",

}

TY - JOUR

T1 - Rotavirus genotypes in malaysia and universal rotavirus vaccination

AU - Lee, Way Seah

AU - Lim, Benjamin Tze Ying

AU - Chai, Pei Fan

AU - Kirkwood, Carl D.

AU - Foo Lee, Jimmy Kok

N1 - Funding Information: The present study was conducted as part of Asian Rotavirus Research Network (ARSN) III research initiatives into the burden of rotavirus disease in the Asia Pacific Region. The present study was funded by an unrestricted research grant from Merck Sharp and Dohme (MSD) Co., Ltd., MSD played no part in the design of the study, data collection or medical writing of the present study. Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 2012/10

Y1 - 2012/10

N2 - Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published data on RV-A hospitalizations and genotypes, mortality on childhood GE and published genotype-specific efficacy data on two RV-A vaccines. Assuming a 95% vaccine coverage, the overall projected effectiveness was 75.7 to 88.1% for Rotateq® and 78.7 to 90.6% for Rotarix® against RVGE-related hospitalizations. The projected annual reduction in RVGE-related deaths was 27 to 32 deaths (from 34 deaths) for Rotateq® and 28 to 32 deaths annually forRotarix®. A universal RV-A vaccine is efficacious in reducing RVGErelated hospitalizations and mortality in Malaysia.

AB - Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published data on RV-A hospitalizations and genotypes, mortality on childhood GE and published genotype-specific efficacy data on two RV-A vaccines. Assuming a 95% vaccine coverage, the overall projected effectiveness was 75.7 to 88.1% for Rotateq® and 78.7 to 90.6% for Rotarix® against RVGE-related hospitalizations. The projected annual reduction in RVGE-related deaths was 27 to 32 deaths (from 34 deaths) for Rotateq® and 28 to 32 deaths annually forRotarix®. A universal RV-A vaccine is efficacious in reducing RVGErelated hospitalizations and mortality in Malaysia.

KW - Group A rotavirus genotypes

KW - Malaysia

KW - Universal vaccination

UR - http://www.scopus.com/inward/record.url?scp=84868272441&partnerID=8YFLogxK

U2 - 10.4161/hv.21577

DO - 10.4161/hv.21577

M3 - Article

C2 - 23022710

AN - SCOPUS:84868272441

SN - 1554-8600

VL - 8

SP - 1401

EP - 1406

JO - Human Vaccines

JF - Human Vaccines

IS - 10

ER -

Rotavirus genotypes in malaysia and universal rotavirus vaccination

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this